Title: Fluvoxamine alone in the treatment of delusional depression
Abstract: Back to table of contents Previous article Next article No AccessFluvoxamine alone in the treatment of delusional depressionPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.153.3.414AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: The aim of this study was to evaluate the efficacy of fluvoxamine in the treatment of delusional depression. METHOD: Fifty- nine inpatients who met the DSM-III-R criteria for major depression with psychotic features were treated with fluvoxamine for 6 weeks. Patients were assessed at baseline and weekly thereafter with the Hamilton Depression Rating Scale and the Dimensions of Delusional Experience rating scale. RESULTS: Of the 57 subjects completed the trial, 84.2% (N=48) recovered. The index episodes of the patients who did not respond to fluvoxamine were of significantly longer duration than those of the responders. CONCLUSIONS: Fluvoxamine has a response rate similar to that of the currently most efficacious treatments for delusional depression, including antidepressants plus antipsychotics and ECT. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byUsing sigma-ligands as part of a multi-receptor approach to target diseases of the brain31 August 2020 | Expert Opinion on Therapeutic Targets, Vol. 24, No. 10The Problem of the Diagnosis and Treatment of Depression by Primary Care Physicians4 December 2019 | Neuroscience and Behavioral Physiology, Vol. 50, No. 1Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, Vol. 119, No. 1De novo variant of TRRAP in a patient with very early onset psychosis in the context of non-verbal learning disability and obsessive-compulsive disorder: a case report13 November 2018 | BMC Medical Genetics, Vol. 19, No. 1Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders18 March 2017Acta Psychiatrica Scandinavica, Vol. 132, No. 5Fundamental & Clinical Pharmacology, Vol. 29, No. 4Journal of Receptors and Signal TransductionTrends in Neurosciences, Vol. 35, No. 12Expert Opinion on Therapeutic Targets, Vol. 15, No. 5Pharmacological characterization of repeated corticosterone injection-induced depression model in ratsBrain Research, Vol. 1359Annals of General Psychiatry, Vol. 9, No. 1Brain Research Reviews, Vol. 61, No. 2Nordic Journal of Psychiatry, Vol. 63, No. 5Annals of General Psychiatry, Vol. 8, No. 1Journal of Pharmacological Sciences, Vol. 110, No. 1The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Psychotic DepressionHarvard Review of Psychiatry, Vol. 16, No. 4Journal of Affective Disorders, Vol. 106, No. 3Journal of Clinical Psychopharmacology, Vol. 28, No. 2Time-Dependent Clearance Decrements of Fluvoxamine in Depressed InpatientsJournal of Clinical Psychopharmacology, Vol. 27, No. 2PSN, Vol. 5, No. 3Biological Psychiatry, Vol. 62, No. 8Jornal Brasileiro de Psiquiatria, Vol. 56, No. 1Biological Psychiatry, Vol. 60, No. 12Psychopathology, Vol. 39, No. 3Expert Review of Neurotherapeutics, Vol. 6, No. 1Drug Safety, Vol. 29, No. 6Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major DepressionJournal of Clinical Psychopharmacology, Vol. 25, No. 5CNS Spectrums, Vol. 10, No. 4International Journal of Clinical Practice, Vol. 59, No. 12Comparison of Two-Phase Treatment With Imipramine or Fluvoxamine, Both Followed by Lithium Addition, in Inpatients With Major Depressive DisorderTom K. Birkenhäger, M.D., Ph.D., Walter W. van den Broek, M.D., Ph.D., Paul G. Mulder, Ph.D., Jan A. Bruijn, M.D., Ph.D., and Peter Moleman, Ph.D.28 January 2015 | American Journal of Psychiatry, Vol. 161, No. 11A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic FeaturesJournal of Clinical Psychopharmacology, Vol. 24, No. 4Psychiatry Research, Vol. 127, No. 1-2Pharmacogenetics, Vol. 14, No. 9Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorderProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, No. 5Diagnostic Specificity and Neuroanatomical Validity of Neurological Abnormalities in First-Episode PsychosesMatcheri S. Keshavan, M.D., Richard D. Sanders, M.D., John A. Sweeney, Ph.D., Vaibhav A. Diwadkar, Ph.D., Gerald Goldstein, Ph.D., Jay W. Pettegrew, M.D., and Nina R. Schooler, Ph.D.1 July 2003 | American Journal of Psychiatry, Vol. 160, No. 7Human Psychopharmacology: Clinical and Experimental, Vol. 18, No. 2Biological Psychiatry, Vol. 53, No. 8Clinical and demographic features of mood disorder subtypesPsychiatry Research, Vol. 112, No. 3A Dynamic Algorithm for the Treatment of Psychotic Major DepressionPsychiatric Annals, Vol. 32, No. 11Human Psychopharmacology: Clinical and Experimental, Vol. 17, No. S1Biological Psychiatry, Vol. 52, No. 5The American Journal of Geriatric Psychiatry, Vol. 9, No. 4Patterns of symptom improvement during antidepressant treatment of delusional depressionPsychiatry Research, Vol. 94, No. 2Current Psychiatry Reports, Vol. 2, No. 4Journal of Psychiatric Research, Vol. 34, No. 2Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 24, No. 2Clinical Neuropharmacology, Vol. 23, No. 6Journal of Clinical Psychopharmacology, Vol. 20, No. 5Clinical and demographic features of psychotic and nonpsychotic depressionComprehensive Psychiatry, Vol. 40, No. 5Symptomatologic analysis of psychotic and non-psychotic depressionJournal of Affective Disorders, Vol. 54, No. 1-2Treatment of Corticosteroid-Induced Mood Changes With OlanzapineE. SHERWOOD BROWN, PH.D., M.D., DAVID A. KHAN, M.D., and TRISHA SUPPES, M.D., PH.D., 1 June 1999 | American Journal of Psychiatry, Vol. 156, No. 6Selective Serotonin Reuptake Inhibitors and Delusional DepressionANTHONY J. ROTHSCHILD, M.D., , and KATHARINE A. PHILLIPS, M.D., 1 June 1999 | American Journal of Psychiatry, Vol. 156, No. 6Depression and Anxiety, Vol. 10, No. 2Treatment-Resistant Depression in Late Life1 December 1998 | Journal of Geriatric Psychiatry and Neurology, Vol. 11, No. 4Venlafaxin for the treatment of psychotic depression16 April 2020 | European Psychiatry, Vol. 13, No. 5Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology15 December 2016 | Journal of Psychopharmacology, Vol. 12, No. 4_supplTwo-Year Outcome of Psychotic Depression in Late LifeAlastair J. Flint, M.B., Ch.B., F.R.C.P.C., F.R.A.N.Z.C.P., and Sandra L. Rifat, Ph.D.1 February 1998 | American Journal of Psychiatry, Vol. 155, No. 2Journal of Affective Disorders, Vol. 49, No. 2Journal of Clinical Psychopharmacology, Vol. 18, No. 6Acta Psychiatrica Scandinavica, Vol. 98, No. 6Human Psychopharmacology: Clinical and Experimental, Vol. 12, No. 3Journal of Clinical Psychopharmacology, Vol. 17, No. 6 Volume 153Issue 3 March 1996Pages 414-416 Metrics PDF download History Published online 1 April 2006 Published in print 1 March 1996
Publication Year: 1996
Publication Date: 1996-03-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 82
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot